Yield10 Bioscience Outlines Plans for Spring 2017 Field

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
64
Yield10 Bioscience Outlines Plans for Spring 2017 Field Tests of Novel Yield Trait Gene C3003 in Camelina and Canola

WOBURN, Mass., March 13, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ: YTEN ) today outlined plans for its Spring 2017 field tests of the novel yield trait gene C3003 in Camelina and canola. The Company expects to begin planting in the second quarter and to report results of the field tests in the fourth quarter of 2017. Yield10 Bioscience is focused on developing proprietary, breakthrough technologies to create step-changes in yield for major food and feed crops to enhance global food security. 

In its Spring 2017 field testing program, Yield10 plans to test both first and second generation versions of its novel yield trait gene C3003 in Camelina, its Fast Field Testing platform oilseed crop for trait discovery and evaluation.   In addition, the Company plans to test first generation C3003 for the first time in field tests in canola, an important oilseed crop in North America.  Key agronomic and growth parameters of the plants will be monitored throughout the field testing and yield data including seed weight, seed size and oil content will be measured and analyzed as compared to control plants.  

“The field tests planned for spring 2017 represent another milestone for Yield10 in the evaluation of our novel yield trait gene C3003, which appears to impact the efficiency of photosynthesis leading to significant improvements in seed yield,” said Kristi Snell, Ph.D., Chief Science Officer of Yield10. “There will be two important ‘firsts’ in this field test—we will test second generation C3003 in Camelina, and we will test first generation C3003 in canola under field conditions. In parallel with our field work this year, we are working to deploy C3003 in soybean and rice to produce plants that can be tested under greenhouse conditions.”     

Background on the Novel Yield Trait Gene C3003

Yield10’s “Smart Carbon Grid for Plants” technology platform focuses on identifying gene targets that enhance carbon capture from photosynthesis and regulate the flow of carbon to seed.  C3003 represents the lead trait in this platform.  C3003 appears to be a very unique gene that impacts photorespiration, a biochemical pathway in C3 plants which is responsible for significant losses in yield. Yield10 is progressing the introduction of the C3003 gene trait and improvements to the C3003 trait, such as the second generation trait, in Camelina, canola, soybean and rice, and expects to report additional results from a number of these activities throughout 2017.    

About Yield10 Bioscience

Yield10 Bioscience, Inc. is focused on developing disruptive technologies for producing step-change improvements in crop yield to enhance global food security.  Yield10 is leveraging an extensive track record of innovation based around optimizing the flow of carbon intermediates in living systems. By working on new approaches to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism to direct more carbon to seed production, Yield10 is advancing several yield traits it has developed in crops such as Camelina, canola, soybean and corn.  Yield10 is based in Woburn, MA. 

For more information about the company, please visit www.yield10bio.com .

(YTEN-G)

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical, including, without limitation, statements regarding the Company's intentions with regard to plans to conduct field tests with Camelina and canola, the results and outcome of those tests, and expectations with regard to the timing of (1) planting for its Spring 2017 field tests and (2) reporting results of greenhouse and field tests, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Yield10 Bioscience's filings with the Securities and Exchange Commission. Yield10 assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

Yield10 Inquiries: Lynne H. Brum, (617) 682-4693, LBrum@yield10bio.com Investor Relations Contact: Amato and Partners, LLC 90 Park Avenue, 17th Floor New York, NY 10016 admin@amatoandpartners.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Photocure Navigates AssureMDx's Medicare Journey

Updated Category News Views 21

Aiming High with AssureMDx Photocure's got this bladder cancer test called AssureMDx that's at the center of its recent moves after acquiring Vesica Health a few months back. This isn't just any test; it's a urine-based, non-invasive way to snag an early look at bladder cancer. With the FDA's Breakthrough Device tag pinned on, they're not just dipping their toes in—this...

Continue Reading
Segway Powersports Ventures into Baja 1000: Ambitions Run High

Updated Category News Views 124

They're gunning for glory in the sands of Baja, folks—Segway Powersports is about to rev up the excitement with its Baja 1000 debut. Never heard before in this legendary race's chronicles, Segway aims to shake up the game with their two brawny Super Villain UTVs. These aren't your run-of-the-pavement ride-ons; they're built for the rough stuff—and if there's a stage...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 172

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
PharmaBlock Forum: Strategic CMC Moves Crucial for Biotech

Updated Category News Views 14

CMC Strategies: The Unsung Hero in Biotech Development Ah, the world of biotech, where one day you're a hero in the lab, and the next you're scrambling to make sense of chemistry, manufacturing, and controls (CMC). It's high time folks started realizing that CMC isn't just procedural drudgery—it's the backbone of making a promising drug go global. That's what the...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 510

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
UAE Pioneers eATA Carnet System Beyond Europe

Updated Category News Views 7

Breaking Tradition with Digital Innovation Well, who would’ve thought? The UAE just leapt ahead in the trade game, becoming the first to roll out the eATA Carnet system beyond the cozy confines of Europe. This isn’t some run-of-the-mill tech rollout, folks. It’s a digital revolution in how temporary imports are handled—goodbye paper, hello efficiency! With this...

Continue Reading
Valmet Expands Board Maker Deal in Asia With New Line

Updated Category News Views 87

If there's one thing Valmet understands, it's the beauty of a longstanding business relationship. On November 9, 2026, the Finnish powerhouse announced another feather in its cap—a new board making line order from a major client in Asia. This deal ain't just another tick in the order books. No, sir, it's about prowess and power in the paper game. Building on Existing...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 370

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
AI Agents Redefine Finance: Deutsche & Ant Tech

Updated Category News Views 16

AI Agents: Shaping the Future of Finance The finance world has always been about numbers and precision, but now, with the advent of AI, it’s entering a domain where machines could call the shots. Hold your horses before you imagine free-wheeling robots in suits; this is still the finance sector, where control and audits are holy grails. Deutsche Bank and Ant's Ambitious...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 490

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading

Top 5 Most Recently Viewed Articles

First Savings Financial Group Shares Exciting Dividend News

Updated Category News Views 159

First Savings Financial Group, Inc. Declares Special Cash Dividend In a recent announcement, First Savings Financial Group, Inc. (NASDAQ: FSFG), a prominent holding company, revealed that their Board of Directors has approved a quarterly cash dividend of $0.16 per common share. This generous dividend is a reflection of the company’s positive financial health and...

Continue Reading
Ransomware Attacks Surge: Insights from Coalition's Findings

Updated Category News Views 222

Ransomware Attacks Surge: Insights from Coalition's Findings SAN FRANCISCO-- Coalition, the world's first Active Insurance provider designed to prevent digital risk before it strikes, has published its latest findings revealing a significant turnaround in the landscape of cyber threats. Recent statistics show that ransomware claims severity has increased by 68%, reaching...

Continue Reading
Metropolitan Commercial Bank's ACH Cloud Shift: Game Changer or Risky Play?

Updated Category News Views 250

On February 17, 2026, Metropolitan Commercial Bank (MCB) completed a major transition by fully retiring its legacy ACH mainframe and moving to Finzly’s cloud-native payment platform. This move positions MCB as a pioneer among U. S. banks as the industry grapples with modernizing aging systems—a reality that has been highlighted by looming regulatory changes. You know...

Continue Reading
GEODIS Names Laura Ritchey President & CEO of Americas Region

Updated Category News Views 401

GEODIS Appoints New President and CEO for the Americas GEODIS, a prominent figure in the logistics and transportation industry, has announced the appointment of Laura Ritchey to the position of President & CEO of its Americas region. In this crucial role, Ritchey will be part of the Group's Executive Board and will report to Marie-Christine Lombard, the Group's Chief...

Continue Reading
Conagra Brands Set to Share Fiscal 2026 Q2 Earnings Announcement

Updated Category News Views 341

Conagra Brands Announces Earnings Release Date Conagra Brands, Inc. (NYSE: CAG) recently made a significant announcement regarding its fiscal 2026 second quarter results. The much-anticipated earnings release is scheduled for a Friday, marking an important milestone for the company and its stakeholders. Details of the Earnings Call The earnings call will take place on a...

Continue Reading